Physician profile
Steven M Fass
NPI 1932188711
$988,645.35
in general payments reported to CMS, 2019-2025
21 companies · $178K in 2025
The $178K reported for 2025 was more than what 99% of Surgery providers received nationally (typical 2025 total: $281).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $101K · 2020: $93K · 2021: $147K · 2022: $163K · 2023: $162K · 2024: $145K · 2025: $178K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Education: $363K · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $61K · Travel and Lodging: $46K · Food and Beverage: $15K.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Education | $363,496.00 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $60,500.00 |
| Travel and Lodging | $46,389.65 |
| Food and Beverage | $14,669.49 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intuitive Surgical, INC. | $987,104.04 | 2019-2025 | Da Vinci Surgical System, Da Vinci Sp |
| Davol INC. | $386.84 | 2019-2024 | Phasix Mesh |
| Ethicon US, LLC | $206.44 | 2019-2023 | Echelon Flex |
| Boston Scientific Corporation | $139.86 | 2025 | Axios |
| Tela Bio, INC. | $116.49 | 2023-2025 | Ovitex Reinforced Bioscaffold With Permanent Polymer (Ovitex) |
| Conmed Corporation | $109.84 | 2020-2021 | |
| Medtronic, INC. | $92.95 | 2023 | Signia, Ligasure |
| Kerecis Limited | $92.92 | 2022-2023 | Kerecis Omega3 Surgiclose, Kerecis Omega3 Marigen, Kerecis Omega3 Graftguide |
| Baxter Healthcare | $61.34 | 2019-2021 | |
| Covidien Lp | $54.54 | 2019 | |
| Endo Pharmaceuticals INC. | $53.12 | 2021 | |
| Standard Bariatrics, INC. | $38.20 | 2022 | |
| W. L. Gore & Associates, INC. | $34.85 | 2023 | Gore Synecor Biomaterial |
| Integra Lifesciences Corporation | $25.02 | 2021 | |
| Misonix INC | $24.77 | 2019 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dilon Technologies, INC. | $24.37 | 2025 | Hemoblast Bellows |
| Innovation Technologies INC | $24.36 | 2024 | Irrisept |
| Mallinckrodt Enterprises LLC | $15.13 | 2019 | |
| Innocoll Pharmaceuticals Limited | $14.33 | 2021 | |
| Tetraphase Pharmaceuticals, INC. | $13.27 | 2020 | |
| Merck Sharp & Dohme LLC | $12.67 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Steven Fass listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.